Interleukin 6: from bench to bedside

By N. Nishimoto, T. Kishimoto. Nature Clinical Practice Rheumatology, 2006

625 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems (2007, background): “The clinical relevance of newly recognized cytokines such as IL-17 and IL-23 has yet to be established in humans, but IL-6 inhibition, which is also under clinical trial with successful results, might have a dual impact on T H 17-mediated immune responses and bon”
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. (2008, methodology): “The designs of these studies were as follows: (1) phase 1 study—a randomized, single-blind, placebo-controlled, intersubject dose-escalation study in which healthy adult men received 0.”
Cytokines in the pathogenesis of rheumatoid arthritis (2007, background): “For example, IL-6 directly regulates the release of the acute-phase proteins from hepatocytes and Kuppffer cells (reviewed in Ref”
Current concepts in the diagnosis and management of cytokine release syndrome. (2014, background): “IL-6 signaling, illustrated in Figure 1, requires binding to cell-associated gp130 (CD130), which is broadly expressed, and the IL-6 receptor (IL-6R) (CD126).(29) IL-6R is cell associated on macrophages, neutrophils, hepatocytes, and someT cells andmediates classic signaling, which predominates when”